Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Curtiss-Wright | CW | Jan 14, 2025 | 359.59 | +2.55 |
Cushing Mlp & Infrastructure Total Return Fund | SRV | Jan 14, 2025 | 46.80 | -0.45 |
Cushman & Wakefield | CWK | Jan 14, 2025 | 12.09 | +1.17 |
Custom Truck One Source | CTOS | Jan 14, 2025 | 4.48 | -0.44 |
Customers Bancorp | CUBI | Jan 14, 2025 | 47.47 | +3.65 |
Customers Bancorp E Pref | CUBI-E | Jan 14, 2025 | 25.81 | +0.31 |
Customers Bancorp F Pref | CUBI-F | Jan 14, 2025 | 25.46 | +0.24 |
Cutera | CUTR | Jan 14, 2025 | 0.40 | +0.40 |
CVB Financial | CVBF | Jan 14, 2025 | 20.48 | +4.49 |
CVD Equipment | CVV | Jan 14, 2025 | 3.86 | +2.39 |
CVR Energy | CVI | Jan 14, 2025 | 20.48 | +0.39 |
Cvr Partners LP Unit | UAN | Jan 14, 2025 | 79.86 | +1.08 |
CVRx | CVRX | Jan 14, 2025 | 16.15 | +7.38 |
CVS Health | CVS | Jan 14, 2025 | 51.57 | +0.10 |
CXApp A | CXAI | Jan 14, 2025 | 1.73 | +2.37 |
CyberArk Software | CYBR | Jan 14, 2025 | 341.51 | +1.09 |
Cybin | CYBN | Jan 14, 2025 | 8.83 | -0.79 |
Cyclacel Pharmaceuticals | CYCC | Jan 14, 2025 | 0.39 | -0.77 |
Cyclacel Pharmaceuticals Pref | CYCCP | Jan 14, 2025 | 8.50 | +13.33 |
Cyclerion Therapeutics | CYCN | Jan 14, 2025 | 2.92 | -9.60 |
Cyclo Therapeutics | CYTH | Jan 14, 2025 | 0.68 | +3.01 |
Cyngn | CYN | Jan 14, 2025 | 0.63 | +36.10 |
Cytek Biosciences | CTKB | Jan 14, 2025 | 7.26 | +0.69 |
Cytokinetics | CYTK | Jan 14, 2025 | 45.23 | -3.17 |
Cytomed Therapeutics | GDTC | Jan 14, 2025 | 2.25 | -0.44 |
CytomX Therapeutics | CTMX | Jan 14, 2025 | 0.84 | -5.23 |
Cytosorbents | CTSO | Jan 14, 2025 | 1.04 | -0.95 |
D-MARKET Electronic Services & Trading ADR | HEPS | Jan 14, 2025 | 3.01 | -0.33 |
D-Wave Quantum | QBTS | Jan 14, 2025 | 4.73 | +23.50 |
D.R. Horton | DHI | Jan 14, 2025 | 143.16 | +3.44 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.